Pharma CVCs have achieved an impressive exit record on the back of successes balancing tools in the innovation toolkit over the past 20 years
Medicine has a tradition of external innovation that predates much pharmaceutical CVC activity. It is perhaps best illustrated by the number of revenue-generating drugs with origins outside the vendor’s own research and development operation, often building on the input of government-funded research and expertise from universities. Development in many cases started with a smaller developer bought by big pharma further down the line, with venture capital supporting the earliest stages of design.
Data compiled for Global Corporate Venturing shows that…
